The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.

Abstract

BACKGROUND:

Parkinson's disease is a progressive neurodegenerative disease, which significantly impacts patients' quality of life and is associated with high treatment and direct healthcare costs. In England, levodopa/carbidopa intestinal gel (LCIG) is indicated for the treatment of levodopa-responsive advanced Parkinson's disease with troublesome motor fluctuations when available combinations of medicinal products are unsatisfactory.

OBJECTIVE:

We aimed to determine the cost effectiveness of LCIG compared to the standard of care for patients with advanced Parkinson's disease in England, using real-world data.

METHODS:

A Markov model was adapted from previous published studies, using the perspective of the English National Health System and Personal and Social Services to evaluate the cost effectiveness of LCIG compared to standard of care in patients with advanced Parkinson's disease over a 20-year time horizon. The model comprised 25 health states, defined by a combination of the Hoehn and Yahr scale, and waking time spent in OFF-time. The base case considered an initial cohort of patients with an Hoehn and Yahr score of ≥ 3, and > 4 h OFF-time. Standard of care comprised standard oral therapies, and a proportion of patients were assumed to be treated with subcutaneous apomorphine infusion or injection in addition to oral therapies. Efficacy inputs were based on LCIG clinical trials where possible. Resource use and utility values were based on results of a large-scale observational study, and costs were derived from the latest published UK data, valued at 2017 prices. The EuroQol five-dimensions-3-level (EQ-5D-3L) instrument was used to measure utilities. Costs and quality-adjusted life-years were discounted at 3.5%. Both deterministic and probabilistic sensitivity analyses were conducted.

RESULTS:

Total costs and quality-adjusted life-years gained for LCIG vs standard of care were £586,832 vs £554,022, and 2.82 vs 1.43, respectively. The incremental cost-effectiveness ratio for LCIG compared to standard of care was £23,649/quality-adjusted life-year. Results were sensitive to the healthcare resource utilisation based on real-world data, and long-term efficacy of LCIG.

CONCLUSIONS:

The base-case incremental cost-effectiveness ratio was estimated to be within the acceptable thresholds for cost effectiveness considered for England.

• Authors: K Ray Chaudhuri, A Simon Pickard, Ali Alobaidi, Yash J Jalundhwala, Prasanna L Kandukuri, Yanjun Bao, Julia Sus, Glynn Jones, Christian Ridley, Julia Oddsdottir, Seyavash Najle-Rahim, Matthew Madin-Warburton, Weiwei Xu, Anette Schrag
• Journal: PharmacoEconomics (Pharmacoeconomics) Vol. 40 Issue 5 Pg. 559-574 (05 2022) ISSN: 1179-2027 [Electronic] New Zealand
• PMID: 35307793 (Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. Crown.

Chemical References

• Antiparkinson Agents
• Drug Combinations
• Gels
• Levodopa
• Carbidopa

Topics

• Antiparkinson Agents (adverse effects, therapeutic use)
• Carbidopa (adverse effects, therapeutic use)
• Cost-Benefit Analysis
• Drug Combinations
• Gels (therapeutic use)
• Humans
• Levodopa (adverse effects, therapeutic use)
• Neurodegenerative Diseases (chemically induced, drug therapy)
• Parkinson Disease (drug therapy)
• Quality of Life